APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Janus Kinase Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cancer Janus Kinase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025197 pages

Choose your research edition.

Industry ResearchCancer Janus Kinase Inhibitors Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Janus Kinase Inhibitors Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Cancer Janus Kinase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Janus Kinase Inhibitors Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Janus Kinase Inhibitors Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Cancer Janus Kinase Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cancer Janus Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Janus Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Janus Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cancer Janus Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Janus Kinase Inhibitors include Eli Lilly, Gilead Sciences, Pfizer, S-BIO, Portola Pharmaceuticals, PIQUR Therapeutics, Moleculin, Kyowa Hakko and Incyte, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Janus Kinase Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Janus Kinase Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Janus Kinase Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Janus Kinase Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Janus Kinase Inhibitors Segment by Company

Eli Lilly

Gilead Sciences

Pfizer

S-BIO

Portola Pharmaceuticals

PIQUR Therapeutics

Moleculin

Kyowa Hakko

Incyte

Hanmi Pharmaceuticals

Dynamic Pharma

Celon Pharmaceuticals

Astra Zeneca

Asana Biosciences

Abbott Laboratories

Cancer Janus Kinase Inhibitors Segment by Type

Pacritinib

Momelotinib

Ruxolitinib

Lestaurtinib

Cancer Janus Kinase Inhibitors Segment by Application

Hospitals

Ambulatory Surgical Centers

Others

Cancer Janus Kinase Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Janus Kinase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Janus Kinase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Janus Kinase Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Janus Kinase Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Janus Kinase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cancer Janus Kinase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cancer Janus Kinase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cancer Janus Kinase Inhibitors Industry Trends Table 2. Cancer Janus Kinase Inhibitors Industry Drivers Table 3. Cancer Janus Kinase Inhibitors Industry Opportunities and Challenges Table 4. Cancer Janus Kinase Inhibitors Industry Restraints Table 5. Global Cancer Janus Kinase Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cancer Janus Kinase Inhibitors Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Cancer Janus Kinase Inhibitors Sales Market Share by Manufacturers Table 9. Global Cancer Janus Kinase Inhibitors Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Cancer Janus Kinase Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cancer Janus Kinase Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cancer Janus Kinase Inhibitors Manufacturers, Product Type & Application Table 13. Global Cancer Janus Kinase Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Janus Kinase Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Pacritinib Table 17. Major Manufacturers of Momelotinib Table 18. Major Manufacturers of Ruxolitinib Table 19. Major Manufacturers of Lestaurtinib Table 20. Global Cancer Janus Kinase Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Cancer Janus Kinase Inhibitors Sales by Type (2021-2026) & (k units) Table 22. Global Cancer Janus Kinase Inhibitors Sales by Type (2027-2032) & (k units) Table 23. Global Cancer Janus Kinase Inhibitors Sales Market Share by Type (2021-2026) Table 24. Global Cancer Janus Kinase Inhibitors Sales Market Share by Type (2027-2032) Table 25. Global Cancer Janus Kinase Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Cancer Janus Kinase Inhibitors Revenue by Type (2021-2026) & (k units) Table 27. Global Cancer Janus Kinase Inhibitors Revenue by Type (2027-2032) & (k units) Table 28. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Type (2021-2026) Table 29. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Ambulatory Surgical Centers Table 32. Major Manufacturers of Others Table 33. Global Cancer Janus Kinase Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Cancer Janus Kinase Inhibitors Sales by Application (2021-2026) & (k units) Table 35. Global Cancer Janus Kinase Inhibitors Sales by Application (2027-2032) & (k units) Table 36. Global Cancer Janus Kinase Inhibitors Sales Market Share by Application (2021-2026) Table 37. Global Cancer Janus Kinase Inhibitors Sales Market Share by Application (2027-2032) Table 38. Global Cancer Janus Kinase Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Cancer Janus Kinase Inhibitors Revenue by Application (2021-2026) & (k units) Table 40. Global Cancer Janus Kinase Inhibitors Revenue by Application (2027-2032) & (k units) Table 41. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Application (2021-2026) Table 42. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Application (2027-2032) Table 43. Global Cancer Janus Kinase Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Cancer Janus Kinase Inhibitors Sales by Region (2021-2026) & (k units) Table 45. Global Cancer Janus Kinase Inhibitors Sales Market Share by Region (2021-2026) Table 46. Global Cancer Janus Kinase Inhibitors Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Cancer Janus Kinase Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Cancer Janus Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Cancer Janus Kinase Inhibitors Sales by Country (2021-2026) & (k units) Table 50. North America Cancer Janus Kinase Inhibitors Sales by Country (2027-2032) & (k units) Table 51. Europe Cancer Janus Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Cancer Janus Kinase Inhibitors Sales by Country (2021-2026) & (k units) Table 53. Europe Cancer Janus Kinase Inhibitors Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Cancer Janus Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Cancer Janus Kinase Inhibitors Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Cancer Janus Kinase Inhibitors Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Cancer Janus Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Cancer Janus Kinase Inhibitors Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Cancer Janus Kinase Inhibitors Sales by Country (2027-2032) & (k units) Table 60. Global Cancer Janus Kinase Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Cancer Janus Kinase Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Cancer Janus Kinase Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Region (2021-2026) Table 64. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Region (2027-2032) Table 65. Eli Lilly Company Information Table 66. Eli Lilly Business Overview Table 67. Eli Lilly Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Eli Lilly Cancer Janus Kinase Inhibitors Product Portfolio Table 69. Eli Lilly Recent Development Table 70. Gilead Sciences Company Information Table 71. Gilead Sciences Business Overview Table 72. Gilead Sciences Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Gilead Sciences Cancer Janus Kinase Inhibitors Product Portfolio Table 74. Gilead Sciences Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Pfizer Cancer Janus Kinase Inhibitors Product Portfolio Table 79. Pfizer Recent Development Table 80. S-BIO Company Information Table 81. S-BIO Business Overview Table 82. S-BIO Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. S-BIO Cancer Janus Kinase Inhibitors Product Portfolio Table 84. S-BIO Recent Development Table 85. Portola Pharmaceuticals Company Information Table 86. Portola Pharmaceuticals Business Overview Table 87. Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio Table 89. Portola Pharmaceuticals Recent Development Table 90. PIQUR Therapeutics Company Information Table 91. PIQUR Therapeutics Business Overview Table 92. PIQUR Therapeutics Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. PIQUR Therapeutics Cancer Janus Kinase Inhibitors Product Portfolio Table 94. PIQUR Therapeutics Recent Development Table 95. Moleculin Company Information Table 96. Moleculin Business Overview Table 97. Moleculin Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Moleculin Cancer Janus Kinase Inhibitors Product Portfolio Table 99. Moleculin Recent Development Table 100. Kyowa Hakko Company Information Table 101. Kyowa Hakko Business Overview Table 102. Kyowa Hakko Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Kyowa Hakko Cancer Janus Kinase Inhibitors Product Portfolio Table 104. Kyowa Hakko Recent Development Table 105. Incyte Company Information Table 106. Incyte Business Overview Table 107. Incyte Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Incyte Cancer Janus Kinase Inhibitors Product Portfolio Table 109. Incyte Recent Development Table 110. Hanmi Pharmaceuticals Company Information Table 111. Hanmi Pharmaceuticals Business Overview Table 112. Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio Table 114. Hanmi Pharmaceuticals Recent Development Table 115. Dynamic Pharma Company Information Table 116. Dynamic Pharma Business Overview Table 117. Dynamic Pharma Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Dynamic Pharma Cancer Janus Kinase Inhibitors Product Portfolio Table 119. Dynamic Pharma Recent Development Table 120. Celon Pharmaceuticals Company Information Table 121. Celon Pharmaceuticals Business Overview Table 122. Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio Table 124. Celon Pharmaceuticals Recent Development Table 125. Astra Zeneca Company Information Table 126. Astra Zeneca Business Overview Table 127. Astra Zeneca Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Astra Zeneca Cancer Janus Kinase Inhibitors Product Portfolio Table 129. Astra Zeneca Recent Development Table 130. Asana Biosciences Company Information Table 131. Asana Biosciences Business Overview Table 132. Asana Biosciences Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Asana Biosciences Cancer Janus Kinase Inhibitors Product Portfolio Table 134. Asana Biosciences Recent Development Table 135. Abbott Laboratories Company Information Table 136. Abbott Laboratories Business Overview Table 137. Abbott Laboratories Cancer Janus Kinase Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Abbott Laboratories Cancer Janus Kinase Inhibitors Product Portfolio Table 139. Abbott Laboratories Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Cancer Janus Kinase Inhibitors Distributors List Table 143. Cancer Janus Kinase Inhibitors Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Cancer Janus Kinase Inhibitors Product Image Figure 2. Global Cancer Janus Kinase Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Janus Kinase Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Janus Kinase Inhibitors Sales (2021-2032) & (k units) Figure 5. Global Cancer Janus Kinase Inhibitors Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cancer Janus Kinase Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Pacritinib Image Figure 9. Momelotinib Image Figure 10. Ruxolitinib Image Figure 11. Lestaurtinib Image Figure 12. Global Cancer Janus Kinase Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Cancer Janus Kinase Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Cancer Janus Kinase Inhibitors Sales Market Share by Type (2021-2032) Figure 15. Global Cancer Janus Kinase Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Cancer Janus Kinase Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Ambulatory Surgical Centers Image Figure 20. Others Image Figure 21. Global Cancer Janus Kinase Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Cancer Janus Kinase Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Cancer Janus Kinase Inhibitors Sales Market Share by Application (2021-2032) Figure 24. Global Cancer Janus Kinase Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Cancer Janus Kinase Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Application (2021-2032) Figure 27. North America Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Cancer Janus Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 29. U.S. Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Cancer Janus Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 34. Germany Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Cancer Janus Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 41. China Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Cancer Janus Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 49. Brazil Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Cancer Janus Kinase Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Cancer Janus Kinase Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Cancer Janus Kinase Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Cancer Janus Kinase Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. North America Cancer Janus Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Cancer Janus Kinase Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Europe Cancer Janus Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Cancer Janus Kinase Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Cancer Janus Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Cancer Janus Kinase Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Cancer Janus Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Cancer Janus Kinase Inhibitors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Cancer Janus Kinase Inhibitors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Pacritinib
  • Momelotinib
  • Ruxolitinib
  • Lestaurtinib
Applications
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Eli Lilly
  • Gilead Sciences
  • Pfizer
  • S-BIO
  • Portola Pharmaceuticals
  • PIQUR Therapeutics
  • Moleculin
  • Kyowa Hakko
  • Incyte
  • Hanmi Pharmaceuticals
  • Dynamic Pharma
  • Celon Pharmaceuticals
  • Astra Zeneca
  • Asana Biosciences
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Janus Kinase Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Janus Kinase Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cancer Janus Kinase Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cancer Janus Kinase Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cancer Janus Kinase Inhibitors Market Dynamics
  1. 2.1 Cancer Janus Kinase Inhibitors Industry Trends
  2. 2.2 Cancer Janus Kinase Inhibitors Industry Drivers
  3. 2.3 Cancer Janus Kinase Inhibitors Industry Opportunities and Challenges
  4. 2.4 Cancer Janus Kinase Inhibitors Industry Restraints
3 Cancer Janus Kinase Inhibitors Market by Manufacturers
  1. 3.1 Global Cancer Janus Kinase Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cancer Janus Kinase Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cancer Janus Kinase Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cancer Janus Kinase Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Janus Kinase Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cancer Janus Kinase Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Cancer Janus Kinase Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Janus Kinase Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Janus Kinase Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Janus Kinase Inhibitors Tier 1, Tier 2, and Tier 3
4 Cancer Janus Kinase Inhibitors Market by Type
  1. 4.1 Cancer Janus Kinase Inhibitors Type Introduction
  2. 4.1.1 Pacritinib
  3. 4.1.2 Momelotinib
  4. 4.1.3 Ruxolitinib
  5. 4.1.4 Lestaurtinib
  6. 4.2 Global Cancer Janus Kinase Inhibitors Sales by Type
  7. 4.2.1 Global Cancer Janus Kinase Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Cancer Janus Kinase Inhibitors Sales by Type (2021-2032)
  9. 4.2.3 Global Cancer Janus Kinase Inhibitors Sales Market Share by Type (2021-2032)
  10. 4.3 Global Cancer Janus Kinase Inhibitors Revenue by Type
  11. 4.3.1 Global Cancer Janus Kinase Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Cancer Janus Kinase Inhibitors Revenue by Type (2021-2032)
  13. 4.3.3 Global Cancer Janus Kinase Inhibitors Revenue Market Share by Type (2021-2032)
5 Cancer Janus Kinase Inhibitors Market by Application
  1. 5.1 Cancer Janus Kinase Inhibitors Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Ambulatory Surgical Centers
  4. 5.1.3 Others
  5. 5.2 Global Cancer Janus Kinase Inhibitors Sales by Application
  6. 5.2.1 Global Cancer Janus Kinase Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Janus Kinase Inhibitors Sales by Application (2021-2032)
  8. 5.2.3 Global Cancer Janus Kinase Inhibitors Sales Market Share by Application (2021-2032)
  9. 5.3 Global Cancer Janus Kinase Inhibitors Revenue by Application
  10. 5.3.1 Global Cancer Janus Kinase Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Janus Kinase Inhibitors Revenue by Application (2021-2032)
  12. 5.3.3 Global Cancer Janus Kinase Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Cancer Janus Kinase Inhibitors Sales by Region
  1. 6.1 Global Cancer Janus Kinase Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Janus Kinase Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Janus Kinase Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Cancer Janus Kinase Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Janus Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cancer Janus Kinase Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cancer Janus Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cancer Janus Kinase Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cancer Janus Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cancer Janus Kinase Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cancer Janus Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cancer Janus Kinase Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cancer Janus Kinase Inhibitors Revenue by Region
  1. 7.1 Global Cancer Janus Kinase Inhibitors Revenue by Region
  2. 7.1.1 Global Cancer Janus Kinase Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cancer Janus Kinase Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Cancer Janus Kinase Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Cancer Janus Kinase Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cancer Janus Kinase Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Cancer Janus Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cancer Janus Kinase Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Cancer Janus Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cancer Janus Kinase Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cancer Janus Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cancer Janus Kinase Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cancer Janus Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Cancer Janus Kinase Inhibitors Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences Cancer Janus Kinase Inhibitors Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Cancer Janus Kinase Inhibitors Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 S-BIO
  20. 8.4.1 S-BIO Company Information
  21. 8.4.2 S-BIO Business Overview
  22. 8.4.3 S-BIO Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 S-BIO Cancer Janus Kinase Inhibitors Product Portfolio
  24. 8.4.5 S-BIO Recent Developments
  25. 8.5 Portola Pharmaceuticals
  26. 8.5.1 Portola Pharmaceuticals Company Information
  27. 8.5.2 Portola Pharmaceuticals Business Overview
  28. 8.5.3 Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Portola Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio
  30. 8.5.5 Portola Pharmaceuticals Recent Developments
  31. 8.6 PIQUR Therapeutics
  32. 8.6.1 PIQUR Therapeutics Company Information
  33. 8.6.2 PIQUR Therapeutics Business Overview
  34. 8.6.3 PIQUR Therapeutics Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 PIQUR Therapeutics Cancer Janus Kinase Inhibitors Product Portfolio
  36. 8.6.5 PIQUR Therapeutics Recent Developments
  37. 8.7 Moleculin
  38. 8.7.1 Moleculin Company Information
  39. 8.7.2 Moleculin Business Overview
  40. 8.7.3 Moleculin Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Moleculin Cancer Janus Kinase Inhibitors Product Portfolio
  42. 8.7.5 Moleculin Recent Developments
  43. 8.8 Kyowa Hakko
  44. 8.8.1 Kyowa Hakko Company Information
  45. 8.8.2 Kyowa Hakko Business Overview
  46. 8.8.3 Kyowa Hakko Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kyowa Hakko Cancer Janus Kinase Inhibitors Product Portfolio
  48. 8.8.5 Kyowa Hakko Recent Developments
  49. 8.9 Incyte
  50. 8.9.1 Incyte Company Information
  51. 8.9.2 Incyte Business Overview
  52. 8.9.3 Incyte Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Incyte Cancer Janus Kinase Inhibitors Product Portfolio
  54. 8.9.5 Incyte Recent Developments
  55. 8.10 Hanmi Pharmaceuticals
  56. 8.10.1 Hanmi Pharmaceuticals Company Information
  57. 8.10.2 Hanmi Pharmaceuticals Business Overview
  58. 8.10.3 Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio
  60. 8.10.5 Hanmi Pharmaceuticals Recent Developments
  61. 8.11 Dynamic Pharma
  62. 8.11.1 Dynamic Pharma Company Information
  63. 8.11.2 Dynamic Pharma Business Overview
  64. 8.11.3 Dynamic Pharma Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Dynamic Pharma Cancer Janus Kinase Inhibitors Product Portfolio
  66. 8.11.5 Dynamic Pharma Recent Developments
  67. 8.12 Celon Pharmaceuticals
  68. 8.12.1 Celon Pharmaceuticals Company Information
  69. 8.12.2 Celon Pharmaceuticals Business Overview
  70. 8.12.3 Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Product Portfolio
  72. 8.12.5 Celon Pharmaceuticals Recent Developments
  73. 8.13 Astra Zeneca
  74. 8.13.1 Astra Zeneca Company Information
  75. 8.13.2 Astra Zeneca Business Overview
  76. 8.13.3 Astra Zeneca Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Astra Zeneca Cancer Janus Kinase Inhibitors Product Portfolio
  78. 8.13.5 Astra Zeneca Recent Developments
  79. 8.14 Asana Biosciences
  80. 8.14.1 Asana Biosciences Company Information
  81. 8.14.2 Asana Biosciences Business Overview
  82. 8.14.3 Asana Biosciences Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Asana Biosciences Cancer Janus Kinase Inhibitors Product Portfolio
  84. 8.14.5 Asana Biosciences Recent Developments
  85. 8.15 Abbott Laboratories
  86. 8.15.1 Abbott Laboratories Company Information
  87. 8.15.2 Abbott Laboratories Business Overview
  88. 8.15.3 Abbott Laboratories Cancer Janus Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Abbott Laboratories Cancer Janus Kinase Inhibitors Product Portfolio
  90. 8.15.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Janus Kinase Inhibitors Value Chain Analysis
  2. 9.1.1 Cancer Janus Kinase Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Janus Kinase Inhibitors Production Mode & Process
  6. 9.2 Cancer Janus Kinase Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Janus Kinase Inhibitors Distributors
  9. 9.2.3 Cancer Janus Kinase Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst